Contact Us
  • Events News
1 min read

San Diego convention Center: June 22 – 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

June 22- 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

Let’s connect! #BioInternationalConvention #SanDiego #USA #AcesoTherapeutics #CysticFibrosis

  • Article details

Category

Events News

Published

June 2, 2026

Reading time

1 min read

Topic

  • Share article
  • Explore more from ACESO

Uncategorized

Research news

Recognition

Publication

Press Release

Keep reading

Related news & insights

  • Company News, Events News, Uncategorized

A proud moment for the entire Aceso Therapeutics team

🏆 A proud moment for the entire Aceso Therapeutics team: ACT-101 has been selected as a winner of the 2026 i-Lab Innovation Competition (28th edition), supported by Bpifrance under the
Read More
  • Company News

SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis

Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for
Read More
  • Publication

European Young Investigators Meeting (EYIM) – March 2026

European Young Investigators Meeting (EYIM) - 2026
Read More
Back to all news

Get in touch

Partner with us to redefine cystic fibrosis care.

Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

Request Information
Investor Relations

Email

contact@aceso-therapeutics.com

Headquarters

Montpellier, France